Related Experiment Video
Updated: May 31, 2026
13:59
High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
Immune effects of trastuzumab
Marianna Nuti1, Filippo Bellati, Valeria Visconti
1"Sapienza" University of Rome, Italy.
Journal of Cancer
|July 1, 2011
Summary
Trastuzumab is a key targeted therapy for HER2-positive breast cancer, inhibiting cancer cell growth. New mechanisms and immunotherapies are emerging to combat HER2-expressing tumors.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Trastuzumab is a cornerstone therapy for HER2-positive breast cancer.
- It functions as a humanized monoclonal antibody targeting the HER2 receptor.
- Its mechanisms of action are continually being uncovered.
Purpose of the Study:
- To review current and emerging therapeutic strategies against HER2-expressing tumors.
- To highlight advancements in targeted therapy and immunotherapy for HER2-positive cancers.
Main Methods:
- Review of existing literature on Trastuzumab and HER2-targeted agents.
- Analysis of novel immunotherapy approaches for HER2-overexpressing cancers.
Main Results:
- Trastuzumab effectively inhibits proliferation and survival of HER2-dependent cancer cells.
- New agents and immunotherapies are being developed to interfere with HER2 signaling and function.
- The immune system is being directed against HER2-overexpressing cells.
Conclusions:
- Trastuzumab remains vital in treating HER2-positive breast cancer.
- Ongoing research is expanding therapeutic options by exploring new mechanisms and immunotherapies.
- Future strategies aim to enhance immune response against HER2-expressing malignancies.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.